Abdulla A. Damluji, MD, PhD Profile picture
Nov 5, 2021 20 tweets 18 min read Read on X
Cardiac Arrest and Cardiogenic Shock

There is a societal paper on this in the works too!

Very important work!

@Babar_Basir @venumenon10

#TCT2021 @TCTMD
Methylprednisone - ? not helpful

Advanced reperfusion strategies - small trial

#TCT2021
SCAI Shock Classification

Milrinone vs Dobutamine - no difference

Gaps in pressers in CICU setting: pressers and antiplatelets

@seanvandiepen @JasonKatzMD

#TCT2021
Invasive hemodynamics monitoring

MCS

Unloading

#TCT2021
Shock Teams - CICU @JACCJournals

3-axis model

HF readmission in shock pt

Excellent @Babar_Basir

#TCT2021

@SandeepNathanMD excellent session
***Multi-vessel PCI in Shock***

First side of the coin

Multivessel PCI should not be performed in shock ??

Culprit Shock: Culprit only

NNT = 12

@thiele_holger

#TCT2021
European guidelines

Long term outcomes

STEM pts?
Culprit lesion only PCI and followed by stage PCI in shock
Multivessel PCI in Shock is Way to Go

ESC Guidelines

CI cross in culprit cross at one year?

Metaanalysis - may be there is benefit?

But there is increased risk in renal failure

Culprit is open label - procedural differences?

@BillONeillMD

#TCT2021
NCSI -

77% improved outcomes with support

Culprit vs NCSI

#TCT2021
Conclusion - too nuanced to tell?

#TCT2021
Decisions to use what device in cardiogenic shock

@SandeepNathanMD
Trials and registry data

Impella vs balloon pump
Impella CP in AMI Shock?

#TCT2021
The Pro Case?

Impella CP as first line in shock

Goal in AMI Shock - improved supply/demand

Hemodynamic Effect of IABP, pLVAD, and ECMO

#TCT2021
IABP in AMI-CS

The longer patients linger? the more likely they die...@behnam_tehrani

#TCT2021
Impella Data

Reducing cardiac work

NCSI data @Babar_Basir
Shock teams in patients from the critical care cardiology network @ShashankSinhaMD
Escalation of Device Therapies

- ECMO + Impella (facilitating LV recovery?)

All good, but we need clinical trials in this space.

So far it is hard to argue with @SandeepNathanMD
Excellent session and great speakers @BinitaShahMD @NavinKapur4

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Feb 3
The Physiology of Hunger: @NEJM

🥸 So this is not in CV medicine, but:
(1) it is interesting and (2) it has implications for CV

😱 Good job @NEJM - Summary

👇👇👇 Image
🥸 1️⃣ Hunger is an ancient survival mechanism that evolved to keep humans alive in times of food scarcity.
🥸 2️⃣ Early humans were hunter-gatherers, who faced unpredictable food supplies. Their bodies adapted to store energy efficiently, to help with survival during famine.
Read 21 tweets
Jan 28
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation: @NEJM

🥸Summary

👇👇👇 Image
🥸 1️⃣ Abelacimab significantly reduced bleeding in atrial fibrillation patients compared to rivaroxaban, as reported in the AZALEA–TIMI 71 trial.
🥸 2️⃣ Monthly subcutaneous abelacimab achieved a 99% reduction in free factor XI levels at 150 mg and 97% at 90 mg.
Read 21 tweets
Jan 7
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: @NEJM

🥸 Vutrisiran is promising: congratulations to authors!

👇👇👇 Image
🥸 1/ ATTR-CM is a progressive, fatal disease. It occurs due to misfolded transthyretin proteins depositing in the heart muscle, causing infiltrative cardiomyopathy. Vutrisiran, an RNA interference agent, offers new therapy by targeting the production of hepatic transthyretin.
🥸 2/ The HELIOS-B trial evaluated vutrisiran in 655 patients with ATTR-CM. Patients were randomized 1:1 to receive vutrisiran (25 mg subcutaneously every 12 weeks) or placebo for up to 36 months.
Read 21 tweets
Dec 21, 2024
Atrial Fibrillation: @JAMA_current

🥸 Nice review in JAMA on AF by @darae_ko and team; congratulations.

😱 20-points here

👇👇👇 Image
🥸 1️⃣ Atrial fibrillation (AF) affects ~10.55 million US adults. It increases the risk of stroke, heart failure (HF), myocardial infarction, chronic kidney disease, dementia, and death.

😱Managing AF effectively is critical to improving CV outcomes.
🥸 2️⃣ AF symptoms range from palpitations, shortness of breath, chest pain, presyncope, and fatigue to being completely asymptomatic.

😱About 10-40% of people with AF don’t notice symptoms, which makes screening and incidental detection critical.
Read 23 tweets
Nov 17, 2024
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM

🥸The SUMMIT trial - @AHAScience

😱 Summary

👇👇👇 Image
🥸 1️⃣ Obesity drives heart failure with preserved ejection fraction (HFpEF) through systemic inflammation and visceral adiposity. Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers weight loss and potential cardiovascular benefits.
🥸 2️⃣ The SUMMIT trial evaluated 731 HFpEF patients with obesity (BMI ≥30), randomized to tirzepatide or placebo for 52 weeks. Primary outcomes were a composite of cardiovascular death or worsening HF events and improvement in health status (KCCQ-CSS).
Read 21 tweets
Nov 17, 2024
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation: @NEJM

🥸The OPTION trial: @AHAScience

😱 Summary

👇👇👇👇 Image
🥸 1️⃣ Oral anticoagulation is standard after atrial fibrillation (AF) ablation for stroke prevention but comes with bleeding risks and patient burdens. Left atrial appendage closure (LAAC) offers an alternative, but data comparing these strategies post-ablation have been limited.
🥸 2️⃣ The OPTION trial evaluated 1,600 patients post-AF ablation, randomized to LAAC (device group) or oral anticoagulation (anticoagulation group). Patients had a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), indicating moderate-to-high stroke risk.
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(